SELECTOPE^TM(Selective Epitope) is a novel antibody development platform technology

   -  PHAGE LIBRARY :  In-house phage libraries of human ScFv(single-chain variable fragments) with large diversity.
   -  CELL-BASED PANNING :  Screening of antibodies against cell surface-expressed target antigens.
   -  3D EPITOPE MAPPING :  Epitope-based antibody classification for functional antibody selection.
   -  ANTIBODY CHARACTERIZATION :  A comprehensive functional evaluation of antibody candidates.

Antigen coating on the plate hides certain epitopes or induces conformational changes, eventually yielding antibodies that recognize unnatural antigens.

Cell-based panning enables the identification of antibodies in a biologically relevant context, augmenting the chances of selecting antibodies with desired specificity.

SLC-M13-01, an in-house developed anti-phage antibody for flow cytometry analysis, empowers accurate and rapid screening of phages without the production of recombinant antibody.

3D Epitope Mapping After Antibody Generation

   1. Organize individual antibodies Into groups according to the binding sites.
   2. Elucidate a group of functional antibodies through competition assay against the ligand of its target.

SLC-3010 is a non-covalent conjugate [conjugated product*] of hIL-2 and anti-hIL-2 antibody (termed as ‘TCB2’).

SLC-3010 selectively stimulates the CD8 T cells and NK cells for anti-cancer immunity, while minimizing the IL-2 exposure to Tregs.

The selectivity is acquired by TCB2, which binds to the IL-2Rα binding site on the IL-2. The non-covalent binding of TCB2 to the IL-2 also prolonged the drug half-life and enhanced the efficacy and safety of IL-2. [* ICH guideline Q5C]

SLC-3010 is the only IL-2 asset that can suppress the Tregs while stimulating the CD8 T and NK cells. This unique MoA is called ‘Triple Action’, and it is achieved by the non-covalency between IL-2 and TCB2.

Initially, SLC-3010 delivers the selective IL-2 signaling to the CD8 T and NK cells, which is same as most of the IL-2 assets (1st Action).

After the initial stimulation, the TCB2 is departed from SLC-3010 while the IL-2 is internalized through endocytosis.

The ‘Free TCB2’ can bind to the endogenous IL-2 that is increased in the activated immune system, and it minimizes the exposure of endo-IL-2 to the Tregs (2nd Action).

Consequently, the complex of endogenous IL-2 and TCB2 can again deliver selective IL-2 signals to the CD8 T and NK cells (3rd Action).

Description will be included.

Description will be included.

Description will be included.